Radius Recycling, Inc. - RDUS STOCK NEWS

Radius Health announced a virtual R&D Webcast on April 5, 2022, focusing on RAD011, its investigational synthetic cannabidiol oral solution. RAD011 targets multiple orphan diseases, including Prader-Willi syndrome, Angelman syndrome, and infantile spasms. The webcast will discuss the asset's history, rationale for different indications, and competitive landscape. The event starts at 10:00 AM EST and will include a 30-minute Q&A. Interested parties can access the call via a provided link or dial-in numbers. A replay will be available later on the company's website.

Radius Health filed a Supplemental New Drug Application (sNDA) with the FDA on February 25, 2022, ahead of schedule. This filing is based on positive results from the Phase 3 ATOM study, which demonstrated significant increases in bone mineral density (BMD) in men with osteoporosis. The FDA's review period is expected to last 10 months. The full dataset from the ATOM study will be presented at the AACE Annual Meeting on May 12-14, 2022. This marks a crucial step for Radius in making TYMLOS available for the treatment of osteoporosis in men.

Radius Health reported Q4 2021 net revenue of $65 million, a 9% increase from Q4 2020. Full-year revenue for TYMLOS was $219 million, up 5% year-over-year. The company achieved a 36% reduction in net loss, totaling ($70 million) for FY 2021, and a 56% improvement in adjusted EBITDA loss of ($24 million).

2022 objectives include projected TYMLOS revenue of $232 million and continued focus on pivotal trials for RAD011. CEO Kelly Martin emphasized a pivotal year for the company with plans for capital returns and enhanced operational effectiveness.

Radius Health, Inc. (NASDAQ: RDUS) will release its fourth quarter and full year 2021 financial results on February 24, 2022. Following the announcement, the company will host a conference call at 8:30 a.m. ET to discuss results and provide updates. Interested parties can join via dial-in or webcast. A replay of the call will be available starting on February 24 at 11:30 a.m. ET through March 3. Radius Health focuses on biopharmaceuticals in bone health, neuroscience, and oncology.

Radius Health, Inc. (NASDAQ: RDUS) has restructured its operations following the completion of three pivotal clinical trials in 2021. The restructuring entailed a reduction of approximately 20% in non-sales headcount, targeting roles supporting the abaloparatide clinical and regulatory activities. While the ATOM and EMERALD studies reported positive outcomes, the wearABLe study failed to meet its primary endpoint. The company is set to report its Q4 and FY 2021 results along with its 2022 outlook on February 24, 2022.

Radius Health announced that the FDA has approved the removal of the boxed warning regarding osteosarcoma risks from the label of TYMLOS, effective December 22, 2021. This decision follows a comprehensive review of long-term post-marketing data. The update aims to provide healthcare professionals and patients with critical information for better treatment decisions. Radius remains focused on exploring further label adjustments with ongoing discussions with the FDA.

The EMERALD trial results revealed that elacestrant significantly improves progression-free survival (PFS) in patients with ER+/HER2- advanced breast cancer. As the first oral selective estrogen receptor degrader (SERD), elacestrant reduced the risk of progression or death by 30% in the overall population and 45% in patients with estrogen receptor mutations (mESR1). The PFS rate at 12 months was 22.32% for elacestrant compared to 9.42% with standard care. Both Menarini and Radius Health are optimistic about the implications of these findings for regulatory submissions in 2022.

BOSTON, Dec. 08, 2021 - Radius Health announced a conference call on December 8, 2021, at 4:00 p.m. ET. The call will discuss topline results from the wearABLe Phase 3 trial and review data from the EMERALD Phase 3 trial presented at the San Antonio Breast Cancer Symposium. Interested parties can join via a domestic dial-in number at 1 (866) 323-7965 or internationally at 1 (346) 406-0961, using conference ID 7691981. A replay will be available later on the same day and archived for 90 days on the Company's website.

Radius Health, Inc. (NASDAQ: RDUS) announced the topline results of its phase 3 wearABLe study, comparing the abaloparatide transdermal system (abalo-TDS) with TYMLOS (abaloparatide subcutaneous injection) in postmenopausal women with osteoporosis. The study did not meet its primary endpoint of non-inferiority, showing a lumbar spine BMD increase of 7.1% for abalo-TDS versus 10.9% for TYMLOS. Both treatments were well tolerated, with no significant safety issues found. The data will inform future plans for abalo-TDS development.